Related Experiment Video
Updated: Mar 21, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
[Dyslipidaemia and atherogenic risk in patients with systemic lupus erythematosus]
José Antonio de Jesús Batún Garrido1, Hugo Alberto Radillo Alba1, Éufrates Hernández Núñez2
1Residente de tercer año de Medicina Interna, Hospital Regional de Alta Especialidad Dr. Gustavo A. Rovirosa Pérez, Villahermosa , Tabasco, México.
Insights
Systemic lupus erythematosus patients often have dyslipidaemia, increasing cardiovascular risk. Higher disease activity and prednisone use are linked to dyslipidaemia, while hydroxychloroquine may be protective.
Area of Science:
- Rheumatology
- Cardiology
- Metabolic Disorders
Background:
- Dyslipidaemia is a frequent comorbidity in patients diagnosed with systemic lupus erythematosus (SLE).
- This comorbidity contributes significantly to the overall health burden and cardiovascular risk in SLE patients.
Purpose of the Study:
- To investigate the prevalence of dyslipidaemia in SLE patients.
- To identify clinical and therapeutic factors associated with dyslipidaemia in this population.
- To assess the atherogenic risk in SLE patients.
Main Methods:
- A cohort of 51 patients with systemic lupus erythematosus was analyzed.
- Data collected included disease variables, medication use, and calculated atherogenic risk indices.
- Statistical analyses, including Chi square, ANOVA, and logistic regression, were employed to determine associations.
Main Results:
- A high prevalence of dyslipidaemia was observed in 68.6% of the patients.
- Significant associations were found between dyslipidaemia and disease activity (SLEDAI), lupus nephritis, and prednisone use (≥20mg/day).
- Conversely, hydroxychloroquine use showed a significant association with the absence of dyslipidaemia.
Conclusions:
- Patients with SLE exhibit a high prevalence of dyslipidaemia and elevated atherogenic risk.
- Factors such as high disease activity (SLEDAI≥4) and significant prednisone use are independently associated with increased dyslipidaemia.
- These findings underscore the heightened cardiovascular risk in SLE patients and highlight potential therapeutic targets.
Introduction:
Dyslipidaemia is a common comorbidity in patients with systemic lupus erythematosus.
Patients And Methods:
Fifty-one patients were included. Variables associated with the disease and the drugs used were recorded. Atherogenic risk was calculated. Chi square was used for categorical variables. ANOVA was performed and a logistic regression model to determine the association of the variables with the presence of dyslipidaemia.
Results:
A percentage of 68.6 had dyslipidaemia. A significant difference between the presence of dyslipidaemia and activity index measured by SLEDAI was found, the presence of lupus nephritis, use of prednisone≥20mg/day, evolution of the disease<3 years. Significance between the absence of dyslipidaemia and use of hydroxychloroquine was found. SLEDAI≥4 and the use of prednisone≥20mg/day were independently associated with the presence of dyslipidaemia. The average of Castelli rate was 5.02, the Kannel index was 2.97 and triglyceride/HDL-C ratio was 5.24.
Conclusions:
Patients with systemic lupus erythematosus have a high prevalence of dyslipidaemia and a high atherogenic rate, which increases cardiovascular risk significantly.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis I: Introduction
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...

